Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?

Further radioligand therapy upon disease progression? If proceeding with further RLT, how many cycles may be planned?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial" by Dr. Amar Kishan.

Answer from: Radiation Oncologist at Academic Institution

I believe this randomized trial does provide high-level evidence that adding 177Lu-PNT2002 prior to SBRT improves PFS compared with SBRT alone. If it were available off trial, yes, I would personally recommend it as an option. Currently, that is not the case.We chose this sequencing because we thoug...

Please select the option that best describes you:

Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?

Related Questions